Hematopoietic Growth Factors

On this page

Erythropoiesis-Stimulating Agents - Red Cell Rally

ESAs mimic endogenous erythropoietin (EPO).

  • Agents: Epoetin alfa, Darbepoetin alfa (longer-acting), Methoxy PEG-epoetin beta.
  • MOA: Activate JAK-STAT pathway on erythroid precursors; increase RBC production.
  • Pharmacokinetics: IV/SC.
    FeatureEpoetin AlfaDarbepoetin Alfa
    Half-life (IV)4-13 hrs~21 hrs (longer)
    GlycosylationStandardIncreased sialic acid
  • Clinical Uses:
    • Anemia of CKD (target Hb 10-12 g/dL)
    • Chemo-induced anemia (non-myeloid)
    • Zidovudine-induced anemia (HIV)
    • Anemia in MDS
    • Reduce allogeneic transfusions (surgery).
  • Adverse Effects:
    • Hypertension (most common)
    • Thrombotic events (MI, stroke, VTE): Risk if Hb > 11-12 g/dL or rises > 1 g/dL/2 wks.
    • PRCA (antibody-mediated)
    • Seizures
    • Potential tumor progression
    • 📌 Mnemonic: EPO causes HHH - Hypertension, Hypercoagulability, Hyperviscosity.
  • Cautions/CI:
    • Uncontrolled hypertension, known hypersensitivity, history of PRCA.
    • Caution: cancer patients not receiving chemotherapy.
  • Monitoring: Monitor: Hb (target 10-12 g/dL, avoid rise > 1 g/dL/2 wks), iron, BP.

⭐ Darbepoetin alfa's significantly longer half-life compared to epoetin alfa is due to its increased sialic acid content from additional glycosylation sites.

Myeloid Growth Factors - Neutrophil Ninjas

Stimulate myeloid progenitor proliferation & differentiation.

  • G-CSF (Granulocyte Colony-Stimulating Factor)

    • Agents: Filgrastim, Pegfilgrastim (long-acting), Lenograstim.
    • MOA: ↑ Neutrophil lineage. 📌 G-CSF for Granulocytes.
    • Clinical Uses:
      • Chemotherapy-induced neutropenia (prophylaxis & treatment, esp. ANC < 500/µL).
      • Bone Marrow Transplant (BMT): PBSC mobilization, accelerates post-transplant neutrophil recovery.
      • Aplastic anemia, congenital neutropenias, Myelodysplastic Syndromes (MDS).
    • Adverse Effects:
      • Bone pain (common), flu-like symptoms, splenic rupture (rare), ARDS.

    ⭐ Pegfilgrastim, a pegylated G-CSF, has a prolonged half-life due to reduced renal clearance, allowing for once-per-chemotherapy-cycle dosing.

  • GM-CSF (Granulocyte-Macrophage CSF)

    • Agents: Sargramostim, Molgramostim.
    • MOA: Broader: ↑ neutrophils, eosinophils, monocytes, macrophages. 📌 GM-CSF for Granulocytes & Macrophages.
    • Clinical Uses:
      • Chemotherapy-induced neutropenia.
      • BMT (post-transplant recovery, engraftment failure).
      • Aplastic anemia.
    • Adverse Effects:
      • Fever, myalgia, arthralgia, rash, capillary leak syndrome, effusions, first-dose reaction (hypotension, dyspnea).

Loading diagram…

Thrombopoietic Growth Factors - Platelet Promoters

  • TPO Receptor Agonists (TPO-RAs):
    • Agents & PK:
      • Romiplostim (SC).
      • Eltrombopag (Oral; chelation with $Ca^{2+}$ - take empty stomach/low-$Ca^{2+}$ meal).
      • Avatrombopag (Oral), Lusutrombopag (Oral).
    • MOA: Mimic TPO → stimulate megakaryopoiesis → ↑ platelet production.
    • Uses:
      • Chronic ITP (target platelets > 50,000/µL).
      • Thrombocytopenia in CLD (pre-procedure).
      • Severe aplastic anemia (Eltrombopag).
    • AEs: Headache, arthralgia, myalgia, marrow reticulin fibrosis (monitor), thromboembolism. Rebound thrombocytopenia (on discontinuation).
      • Eltrombopag: Hepatotoxicity (monitor LFTs).

⭐ Eltrombopag is an oral, non-peptide TPO receptor agonist that must be taken on an empty stomach or with a low-calcium meal to avoid chelation with polyvalent cations.

  • Interleukin-11 (IL-11):
    • Agent & PK: Oprelvekin (SC) - less used.
    • MOA: Stimulates various hematopoietic cells, including megakaryocyte progenitors.
    • Uses: Prevention of severe thrombocytopenia post-myelosuppressive chemo (non-myeloid malignancies).
    • AEs: Fluid retention (edema, dyspnea), atrial arrhythmias (tachycardia, fibrillation), fatigue, headache. 📌 Oprelvekin (IL-11) makes you 'swell-even'.

High‑Yield Points - ⚡ Biggest Takeaways

  • Erythropoietin (EPO) & Darbepoetin alfa stimulate RBCs; treat anemia of CKD.
  • G-CSF (Filgrastim, Pegfilgrastim) boosts neutrophils; for chemotherapy-induced neutropenia.
  • GM-CSF (Sargramostim) stimulates myeloid lineages; used in aplastic anemia, BMT.
  • TPO agonists (Romiplostim, Eltrombopag) ↑ platelets; treat ITP.
  • EPO adverse effects: hypertension, thrombosis, pure red cell aplasia (PRCA).
  • Oprelvekin (IL-11) ↑ platelets; side effects (fluid retention) limit use.
  • Monitor hemoglobin with EPO; target <12 g/dL to avoid thrombosis.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Hematopoietic Growth Factors

  1. 1. Which drug inhibits granulocyte migration by binding tubulin and disrupting microtubule assembly?

    • A. Montelukast
    • B. Colchicine
    • C. Cromoglycate
    • D. Indomethacin
    Show answer

    Answer: B. Colchicine

    Colchicine - Colchicine binds tubulin and disrupts microtubule assembly, thereby inhibiting granulocyte migration and chemotaxis. - This mechanism is important in acute gout, where it prevents neutrophil accumulation and reduces inflammation around urate crystal deposits. Cromoglycate - Cromoglycate is a mast-cell stabilizer that prevents release of inflammatory mediators, rather than directly interfering with granulocyte movement. - Its principal action is inhibition of mast-cell degranulation, whereas granulocyte migration is specifically impaired by colchicine’s effects on microtubules. Montelukast - Montelukast is a leukotriene receptor antagonist that blocks leukotriene-mediated bronchoconstriction and inflammation. - Although it modifies inflammatory responses, it does not directly inhibit granulocyte chemotaxis or migration through disruption of microtubule function. Indomethacin - Indomethacin inhibits cyclooxygenase and can also inhibit leukocyte motility, but it does not bind tubulin; it therefore does not produce the microtubule-mediated inhibition asked for here.

  2. 2. Romiplostim mimics the action of which endogenous mediator?

    • A. Interleukin eight
    • B. Interleukin six
    • C. Thrombopoietin
    • D. Prostaglandin E one
    Show answer

    Answer: C. Thrombopoietin

    Thrombopoietin - Romiplostim is a thrombopoietin receptor agonist that mimics endogenous thrombopoietin by activating its receptor on megakaryocyte-lineage cells. - This signaling stimulates megakaryopoiesis and platelet production in the bone marrow, making thrombopoietin the correct choice. Interleukin eight - IL-8 is a chemokine that primarily promotes neutrophil chemotaxis and inflammation, rather than regulating platelet production through the thrombopoietin pathway. - Romiplostim does not target IL-8 signaling; it increases platelet production by activating the thrombopoietin receptor in megakaryocyte-lineage cells. Interleukin six - IL-6 contributes to inflammation, immune responses, and hematopoiesis, but it is not the principal receptor pathway activated by romiplostim. - Although IL-6 may influence platelet production indirectly, romiplostim directly stimulates the thrombopoietin receptor to increase platelet formation. Prostaglandin E one - PGE1 is a prostaglandin that causes vasodilation and inhibits platelet aggregation, affecting platelet function and vascular tone rather than platelet production. - Romiplostim acts through the thrombopoietin receptor, so its mechanism is distinct from prostaglandin-mediated effects.

  3. 3. Which rare syndrome has been reported in association with montelukast treatment?

    • A. Drug-induced lupus
    • B. Goodpasture syndrome
    • C. Idiopathic pulmonary fibrosis
    • D. Churg-Strauss syndrome
    Show answer

    Answer: D. Churg-Strauss syndrome

    Churg-Strauss syndrome - Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) has been reported during montelukast treatment, making it an atypical adverse association. - The syndrome may reflect unmasking of underlying vasculitis when corticosteroids are tapered or withdrawn, rather than a direct montelukast effect. Drug-induced lupus - Drug-induced lupus is classically associated with drugs such as hydralazine and procainamide, not montelukast. Goodpasture syndrome - Goodpasture syndrome causes pulmonary hemorrhage and rapidly progressive glomerulonephritis through anti-glomerular basement membrane antibodies. - There is no established association between montelukast use and Goodpasture syndrome, so it does not fit the atypical side effect. Idiopathic pulmonary fibrosis - Idiopathic pulmonary fibrosis is a fibrosing interstitial lung disease, not the characteristic vasculitic association reported with montelukast.

  4. 4. Which iron-study pattern is typical of uncomplicated iron deficiency anemia in the absence of inflammation or liver disease?

    • A. Decreased TIBC, decreased serum ferritin
    • B. Decreased TIBC, increased serum ferritin
    • C. Increased TIBC, decreased serum ferritin
    • D. Increased TIBC, increased serum ferritin
    Show answer

    Answer: C. Increased TIBC, decreased serum ferritin

    Increased TIBC, decreased serum ferritin is the typical pattern of uncomplicated iron deficiency anemia because depleted stores lower ferritin and increase transferrin production. Low ferritin is highly specific for depleted iron stores, but inflammation may elevate ferritin and mask deficiency. Increased TIBC, increased serum ferritin is not the typical uncomplicated pattern because ferritin is expected to fall. Decreased TIBC, increased serum ferritin is characteristic of anemia of inflammation. Decreased TIBC, decreased serum ferritin can occur when iron deficiency coexists with inflammation or impaired transferrin synthesis, but it is not the typical uncomplicated pattern.

  5. 5. An Rh(D)-positive, nonsplenectomized adult with newly diagnosed immune thrombocytopenia has significant mucosal bleeding without hemodynamic instability or hemolysis. Which drug is NOT used for initial platelet-raising treatment?

    • A. IV immunoglobulin
    • B. Oral prednisolone
    • C. Oral eltrombopag
    • D. Anti-D immunoglobulin
    Show answer

    Answer: C. Oral eltrombopag

    Oral eltrombopag - Eltrombopag is a thrombopoietin receptor agonist that increases platelet production and is primarily used for chronic idiopathic thrombocytopenic purpura. - Its delayed platelet response takes several days, so it is not appropriate for the immediate management of an acute bleeding crisis. Oral prednisolone - Prednisolone is a first-line corticosteroid for acute ITP because it suppresses immune-mediated platelet destruction and antibody production. - Although its effect is slower than IVIG, it helps raise platelet counts and is used during bleeding episodes. Anti-D immunoglobulin - RhIG can raise platelet counts in appropriately selected Rh(D)-positive, nonsplenectomized patients without hemolysis-related contraindications, but it carries a risk of serious hemolysis IV immunoglobulin - Intravenous immunoglobulin blocks Fc receptors on macrophages, reducing destruction of antibody-coated platelets. - It is a first-line treatment for severe bleeding or very low platelet counts because it can increase platelet counts rapidly. Reference - Title: Updated International Consensus Report on Primary Immune Thrombocytopenia - Year: 2019 - Sections: Initial treatment; Emergency treatment

  6. 6. A stable adult with chronic kidney disease has haemoglobin 8 g/dL despite adequate iron stores and correction of other reversible causes. What is the most appropriate long-term treatment for the anaemia?

    • A. Oral iron therapy
    • B. Androgenic steroids
    • C. Erythropoietin therapy
    • D. Packed cell transfusion
    Show answer

    Answer: C. Erythropoietin therapy

    Erythropoietin therapy - Erythropoiesis-stimulating agents replace the deficient erythropoietic stimulus caused by damaged kidneys, addressing the major mechanism of anemia in CRF. - By stimulating bone marrow red-cell production, ESAs improve hemoglobin and associated symptoms such as fatigue and exercise intolerance. Oral iron therapy - Oral iron addresses iron deficiency but does not correct the primary problem in CRF: inadequate endogenous erythropoietin production by damaged kidneys. - Functional iron deficiency from chronic inflammation can impair iron utilization, so oral iron alone is often insufficient to correct renal anemia. Androgenic steroids - Androgenic steroids may stimulate erythropoiesis, but they are less favorable than ESAs because of significant adverse effects, including hepatotoxicity and virilization. - Their limited role reflects risks such as cardiac complications and use mainly when primary treatments are ineffective or unavailable. Packed cell transfusion - Packed cell transfusion rapidly raises hemoglobin but is not preferred for long-term management because of iron overload, alloreactions, and other complications. - Transfusion is reserved for acute severe anemia or selected situations when ESAs are ineffective or contraindicated, rather than used as routine therapy.

  7. 7. In an adult with iron-deficiency anaemia and no urgent need for correction, which situation is LEAST likely to require intravenous iron?

    • A. Gastrointestinal intolerance to oral iron
    • B. Impaired gastrointestinal iron absorption
    • C. Erythropoietin therapy without haemodialysis
    • D. Gastrointestinal losses exceeding oral replacement
    Show answer

    Answer: C. Erythropoietin therapy without haemodialysis

    Erythropoietin therapy without haemodialysis is the least likely situation to require intravenous iron because erythropoietin use alone does not mandate intravenous replacement; oral iron may suffice if tolerated and adequately absorbed when there is no urgent correction requirement. Intravenous iron is commonly used with erythropoietin during haemodialysis to meet increased iron requirements and replace ongoing losses. Gastrointestinal intolerance to oral iron supports intravenous replacement when oral treatment cannot be continued. Gastrointestinal losses exceeding oral replacement support intravenous iron because oral replacement cannot compensate for the losses; controlled intermittent gastrointestinal blood loss may instead be managed with oral iron. Impaired gastrointestinal iron absorption supports intravenous replacement because gastrointestinal uptake is inadequate.

  8. 8. Which isotope is used to measure RBC volume?

    • A. Cr-51
    • B. H-3
    • C. Na-24
    • D. I-131
    Show answer

    Answer: A. Cr-51

    Cr-51 - Chromium-51 binds mainly to the beta chains of hemoglobin to label red blood cells, but approximately 1% of the label elutes daily. - The dilution of labeled cells throughout the circulation permits calculation of total RBC mass and volume, making Cr-51 the appropriate isotope. H-3 - Tritium (H-3) is commonly administered as tritiated water to measure total body water, because it equilibrates throughout the body's fluid compartments. - It does not specifically label erythrocytes or bind to hemoglobin, so it cannot directly determine total RBC volume. Na-24 Na-24 is used to assess exchangeable sodium rather than RBC volume. It does not specifically label erythrocytes. I-131 I-131 is not the standard erythrocyte label for measuring RBC volume. I-131-labelled albumin has been used to measure plasma volume, which is a different blood compartment.

  9. 9. Which vein is a site of proximal lower-limb deep vein thrombosis?

    • A. Femoral vein
    • B. Posterior tibial vein
    • C. Fibular vein
    • D. Anterior tibial vein
    Show answer

    Answer: A. Femoral vein

    Femoral vein thrombosis is proximal DVT; Anterior tibial vein, Posterior tibial vein and Fibular vein thromboses are distal calf DVT.

  10. 10. What is the typical bone marrow finding in myelofibrosis?

    • A. Megaloblast-rich aspirate
    • B. Plasma-cell-rich aspirate
    • C. Ring-sideroblast-rich aspirate
    • D. Dry tap
    Show answer

    Answer: D. Dry tap

    Dry tap is characteristic because marrow fibrosis impedes aspiration. Megaloblast-rich aspirate suggests megaloblastic hematopoiesis, usually from vitamin B12 or folate deficiency. Plasma-cell-rich aspirate suggests a plasma-cell proliferation or reactive plasmacytosis. Ring-sideroblast-rich aspirate indicates sideroblastic erythropoiesis rather than the characteristic aspiration result of myelofibrosis.

Flashcards: Hematopoietic Growth Factors

  1. 1. Ruxolitinib is used to treat chronic myeloproliferative disorders that have _____ mutations including _____ and _____

    Show answer

    JAK2 · myelofibrosis · polycythemia vera

  2. 2. approved for the treatment of thrombocytopenia with chronic liver disease.

    Show answer

    Avatrombopag

  3. 3. Patients with sickle cell anemia should not receive pegylated filgrastim as it can trigger a .

    Show answer

    sickle cell crisis

  4. 4. Hematological complications of Trimethoprim (TMP) use include _____ (granulocytopenia, leukopenia) and _____

    Show answer

    pancytopenia · megaloblastic anemia

  5. 5. Immune thrombocytopenia can be treated with the TPO receptor agonists _____ and _____

    Show answer

    eltrombopag · romiplostim

  6. 6. is an oral HIF prolyl hydroxylase inhibitor, used to treat anemia in CKD.

    Show answer

    Daprodustat

  7. 7. _____ is given to treat _____ secondary to _____ therapy.

    Show answer

    Oprelvekin · thrombocytopenia · anti-cancer

  8. 8. _____ is considered superior to all other parenteral iron supplementation especially for _____ IDA.

    Show answer

    Ferric carboxymaltose · postpartum

  9. 9. Treatment of hemophilia A involves _____ plus recombinant _____

    Show answer

    desmopressin · factor VIII

  10. 10. _____ is a competitive _____ of _____

    Show answer

    Vorapaxar · antagonist · PAR-1

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF